文献速递肿瘤 PET/CT

代谢风险评分在大B细胞淋巴瘤各亚型中的预后价值存在差异:一项真实世界分析

Divergent prognostic utility of metabolic risk scores in large B-cell lymphoma subtypes: a real-world analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-06-16

该研究回顾性分析了本机构接受R-CHOP方案治疗的LBCL患者的基线[18F]FDG-PET/CT,比较四种代谢风险评分在tNHL、DHL/THL、PMBL等亚型中的预后表现,并与既往发表的DLBCL, NOS队列对照。结果显示不同亚型的最优评分不同:tNHL中IMPI的C-index最高但不及IPI,DHL/THL中MTV/WHO PS最高,PMBL中临床PET评分最高。

要点

  • tNHL中IMPI在代谢风险评分中C-index最高,但被IPI超越。
  • DHL/THL中MTV/WHO PS的C-index最高,PMBL中临床PET评分最高。
  • SDmax改善PMBL和tNHL的预后预测,但未改善DHL/THL。

核心结论

  • 代谢风险评分在大B细胞淋巴瘤各亚型中的预后价值存在差异。
  • 亚型特异性代谢模型可能改善个体化风险分层并指导治疗策略。

研究设计与样本

  • 回顾性分析本机构接受R-CHOP方案治疗的LBCL患者的基线[18F]FDG-PET/CT。
  • 纳入tNHL(n=88)、DHL/THL(n=32)、PMBL(n=26)及其他(n=49),并与既往发表的DLBCL, NOS队列(n=355)比较。
  • 计算MTV、SDmax和肿瘤表面体积比等代谢参数,应用IMPI、MTV/WHO PS、MTV/SDmax和临床PET模型四种代谢风险评分,以Harrell's C-index评估预后性能,并为tNHL建立多变量模型。

主要发现

  • tNHL中IMPI在代谢风险评分中对PFS、OS、TTP和12个月内疾病进展的C-index最高,但被IPI超越。
  • DHL/THL中MTV/WHO PS的C-index最高。
  • PMBL中临床PET评分的C-index最高。
  • SDmax改善PMBL和tNHL的预后预测,但未改善DHL/THL。
  • 多变量分析确定tNHL中PFS的独立预测因素包括IPI和SUVmean。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Large B-cell lymphomas (LBCL) include diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), and subtypes such as transformed non-Hodgkin's lymphoma (tNHL), primary mediastinal B-cell lymphoma (PMBL), and double/triple-hit lymphomas (DHL/THL). While metabolic risk scores based on metabolic tumor volume (MTV) have demonstrated prognostic value in DLBCL, NOS, their applicability to other LBCL subtypes remains unclear. METHODS: Baseline [18F]FDG-PET/CT scans of LBCL patients treated with R-CHOP regimens at our institution were retrospectively analyzed. Metabolic parameters, including MTV, lesion dissemination (SDmax) and tumor surface volume ratio were calculated for each histological subgroup. Four metabolic risk scores-the international metabolic prognostic index (IMPI), MTV/WHO PS, MTV/SDmax and Clinical PET model- were applied to calculate progression risk in LBCL subtypes. Harrell's C-index evaluated the prognostic performance. A multivariable model was developed for tNHL. RESULTS: We included tNHL (n = 88), DHL/THL (n = 32), PMBL (n = 26) and others (n = 49), and compared them to a cohort of previously published DLBCL, NOS (n = 355). IMPI demonstrated the highest C-index amongst the metabolic risk scores in tNHL for progression-free survival (PFS), overall survival, time to progression and progression of disease within 12 months, but was outperformed by the IPI. For DHL/THL the highest C-indices were observed for MTV/WHO PS. For PMBL the clinical PET score showed the highest C-indices. SDmax improved prognostic predictions in PMBL and tNHL, but not in DHL/THL. Multivariate analysis identified independent predictors of PFS in tNHL, including IPI and SUVmean. CONCLUSION: Metabolic risk scores show variable prognostic value across LBCL subtypes. Subtype-specific metabolic models may enhance personalized risk stratification and guide treatment approaches.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Vergote VKJ, Verhoef G, Janssens A, et al. Divergent prognostic utility of metabolic risk scores in large B-cell lymphoma subtypes: a real-world analysis. Eur J Nucl Med Mol Imaging. 2025. PMID: 40518458. doi:10.1007/s00259-025-07368-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。